Carmignac Gestion’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$413K Sell
14,495
-4,980
-26% -$132K 0.01% 114
2026
Q2
$469K Buy
+19,475
New +$509K 0.01% 92
2023
Q2
– Sell
-46,120
Closed -$1.88M – 180
2023
Q1
$1.88M Sell
46,120
-24,336
-35% -$1.05M 0.03% 95
2022
Q4
$3.61M Buy
70,456
+37,312
+113% +$1.79M 0.07% 78
2022
Q3
$1.45M Sell
33,144
-1,166,286
-97% -$56.7M 0.03% 84
2022
Q2
$62.9M Sell
1,199,430
-1,447,517
-55% -$73.8M 1.33% 24
2022
Q1
$137M Buy
2,646,947
+711,627
+37% +$36.9M 2.21% 18
2021
Q4
$114M Buy
+1,935,320
New +$95.9M 1.6% 19
2019
Q4
– Sell
-3,399,591
Closed -$116M – 134
2019
Q3
$116M Buy
+3,399,591
New +$124M 1.46% 26

Other funds holding PFE

Carmignac Gestion's PFE Position: Q3 2026 in Review

Carmignac Gestion reduced its Pfizer (PFE) stake by 26% in Q3 2026, selling an estimated $132K and leaving 14,495 shares worth $413K. The position accounts for 0.01% of the portfolio, ranked #114.

Carmignac Gestion first reported a position in PFE in Q3 2019 and has held it in 9 quarters since. The position peaked at $137M in Q1 2022. 2,920 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Carmignac Gestion held 14,495 shares of Pfizer worth $413K as of Q3 2026.
  • Carmignac Gestion sold 4,980 Pfizer shares in Q3 2026, an estimated $132K.
  • Pfizer made up 0.01% of Carmignac Gestion's portfolio in Q3 2026, its #114 holding.
  • Carmignac Gestion first reported a position in Pfizer in Q3 2019 and has held it in 9 quarters since.
  • Carmignac Gestion's Pfizer position peaked at $137M in Q1 2022.
  • 2,920 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Carmignac Gestion's 13F filing for Q3 2026, filed 13 Nov 2026.